Pulmatrix, Inc.

Snapshot

Pulmatrix is a clinical-stage biotech that has stopped developing its own drugs and is instead trying to survive through a reverse merger. FY 2025 revenue was $0 and the company lost $5.2M.

What's Happening Right Now

• Tue 27th Oct '26 · Merger vote passed: On Oct 26, 2026, Pulmatrix stockholders approved all nine merger proposals with Eos SENOLYTIX, including the share issuance, change of control, a 1-for-2 to 1-for-10 reverse split, and raising authorized shares to 250 million, clearing a key closing condition for the deal that will leave legacy Pulmatrix holders with roughly 6% of the combined company.
• Mon 26th Oct '26 · Dilution registration: Pulmatrix filed a prospectus on Oct 26, 2026 registering roughly 528,668 shares (about 13-14% of shares outstanding) issuable to RCM Eos PIPE HOLDINGS on conversion of Series B Preferred plus dividend shares, which convert automatically when the Eos merger closes.
• Thu 22nd Oct '26 · Eos pipeline data: Merger partner Eos SENOLYTIX presented preclinical survival data for its lead candidate PTC-2105 at an October 2026 mitochondria conference, part of its push toward first-in-human sarcopenia trials ahead of the planned Q4 2026 merger close.
• Thu 22nd Oct '26 · Registration: Registered 492K shares for sale on Form S-3.
• Tue 20th Oct '26 · Price action: Shares broke below their 50-day moving average on Oct 20, 2026, trading as low as $1.35 on thin volume of about 37,000 shares.
• Thu 13th Aug '26 · Going concern: Pulmatrix's Q2 2026 10-Q (filed Aug 13, 2026) disclosed substantial doubt about its ability to continue as a going concern, with just $2.2 million cash and all clinical development on hold while it seeks to monetize its pipeline, absent the Eos merger closing.
• Thu 16th Apr '26 · Offering: Raised $1.00M in gross proceeds through a private placement (PIPE).
• Thu 9th Apr '26 · Convertible: Issued a $2.50M convertible note.